Biden Team to Help AstraZeneca Find U.S. Plant After Mixup
- J&J taking over Emergent plant means no mix-up risk, aides say
- Astra agreed to leave, production delays are not anticipated
This article is for subscribers only.
President Joe Biden’s administration is working with AstraZeneca Plc to find new manufacturing capacity in the U.S. after the company agreed to abandon a Baltimore Covid-19 vaccine plant that will focus exclusively on making doses for Johnson & Johnson.
The talks are the latest development after an error at the Emergent BioSolutions Inc. facility -- in which ingredients for the two companies’ vaccines were mixed up -- led to a batch of 15 million doses worth of drug substance being spoiled.